Autoimmune disease
Therapeutic area
Immunology
Rare disease
No
- Definition
- A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Autoimmune disease
- Therapeutic area
- Immunology
- autoimmune disease
- autoimmune disease
- autoimmune disease or disorder
- autoimmune disorder
- disease, autoimmune
- All therapeutic areas
- Immunology
- Severity
- Severe
- MONDO ID
- MONDO:0007179
- Parent condition
- MONDO:0005046
Related records
Broader conditions (4)
- Disease
- Disease by body system or component
- Human disease
- Immune system disorder
Narrower conditions (265)
- AChR+ myasthenia gravis
- Acquired epidermolysis bullosa
- Acute inflammatory demyelinating polyradiculoneuropathy
- Acute motor and sensory axonal neuropathy
- Acute motor axonal neuropathy
- Acute pure sensory neuropathy
- Acute sensory ataxic neuropathy
- Adult-onset myasthenia gravis
- Alopecia universalis onychodystrophy vitiligo
- Ankylosing spondylitis
- Anti-glomerular basement membrane disease
- Anti-neutrophil antibody associated vasculitis
- Anti-p200 pemphigoid
- Antiphospholipid syndrome
- Arthus reaction
- Atrophic thyroiditis
- Autoerythrocyte sensitization syndrome
- Autoimmune atherosclerosis
- Autoimmune autonomic ganglionopathy
- Autoimmune bullous skin disease
Trials (903)
- "ADEN Platform: Pilot Clinical Validation for Chronic Disease Risk Stratification in Colombia"
- "Circulating Fetal DNA, Pregnancy And Immune Diseases"
- 18F-DPA-714 PET/MR in Dysfunctional Brain Diseases
- 18F-FDG PET/CT for IgG4-Related Disease
- 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis
- A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
- A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
- A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases
- A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
- A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
- A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
- A Dose Escalating Study of HC002 in Healthy Adult Volunteers
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
- A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
Approved drugs (1)
- Amifampridine phosphate
Drugs in development (71)
- Abiprubart Phase 2
- Amlitelimab Phase 1
- Atuzabrutinib Phase 1
- Balixafortide Phase 1
- Batoclimab Phase 1
- Belumosudil Phase 1
- Belumosudil mesylate Phase 1
- Bempikibart Phase 1
- Branebrutinib Phase 1
- Cepeprubart Phase 2
- Daxdilimab Phase 1
- Dazdotuftide Phase 2
- Dazodalibep Phase 1
- Edralbrutinib Phase 1
- Efgartigimod alfa Phase 1
- Fenebrutinib Phase 1
- Filgotinib maleate Phase 1
- Flizasertib Phase 1
- Frexalimab Phase 1
- Gamcemetinib Phase 1